Merck & Co., Inc. (MRK)

Merck & Co., Inc. (NYSE: MRK) is a global pharmaceutical company that develops and manufactures prescription medicines, vaccines, and animal health products. Its major products include Keytruda, Gardasil, Januvia, Bridion, and Lynparza. (SIC: 2834; Headquarters: Rahway, New Jersey, USA; Incorporated: New Jersey, USA; Fiscal Year End: December 31; SEC Filing Category: Large accelerated filer.)

TickerMRK
CompanyMerck & Co., Inc.
ExchangeNYSE
HeadquartersRAHWAY, NJ

Income statement — period ending 2026-06-30

Comprehensive Income (Loss), Net of Tax, Attributable to Parent-$1,217,000,000
Cost of Goods and Services Sold$4,395,000,000
Earnings Per Share, Basic-1 USD/shares
Earnings Per Share, Diluted-1 USD/shares
Gross Profit (derived)$12,212,000,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest-$683,000,000
Income Tax Expense (Benefit)$654,000,000
InterestExpenseNonoperating$525,000,000
Investment Income, Interest$35,000,000
Net Income (Loss) Attributable to Parent-$1,335,000,000
Net Income (Loss) Attributable to Noncontrolling Interest-$2,000,000
Net Income (Loss) Available to Common Stockholders, Basic-$1,335,000,000
Other Nonoperating Income (Expense)-$99,000,000
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest-$1,337,000,000
Research and Development Expense$9,741,000,000
Restructuring Charges$151,000,000
Revenues$16,607,000,000
Selling, General and Administrative Expense$2,904,000,000
Share-based Payment Arrangement, Noncash Expense$483,000,000
Weighted Average Number of Shares Outstanding, Diluted2,470,000,000 shares
Weighted Average Number of Shares Outstanding, Basic2,470,000,000 shares

Sourced from SEC EDGAR/XBRL filings via StockSpectro.

View full interactive research on StockSpectro